Crofelemer, jaguar health's prescription drug conditionally approved by the fda for chemotherapy-induced diarrhea in dogs, is the subject of the company's investigational new animal drug application for the indication of general diarrhea in dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no fda-approved anti-secretory agents to treat canine diarrhea san francisco, ca / accesswire / may 6, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that it has established a new investigational new animal drug (inad) file with the center for veterinary medicine (cvm) of the u.s. food and drug administration (fda) for the company's novel plant-based prescription drug crofelemer to treat general, non-infectious diarrhea in dogs. crofelemer delayed-release tablets, under the name canalevia®-ca1, received conditional approval in december 2021 from the fda for the treatment of chemotherapy-induced diarrhea (cid) in dogs.
JAGX Ratings Summary
JAGX Quant Ranking